EGFR-targeting as a biological therapy: Understanding Nimotuzumab's clinical effects

Cancers

Volumn 3, Issue 2, 2011, Pages 2014-2031

  Perez, Rolando ^a   Moreno, Ernesto ^a   Garrido, Greta ^a   Crombet, Tania ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Biological therapy; Cancer treatment; EGFR; Nimotuzumab; Targeted therapy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IPILIMUMAB; IRINOTECAN; NAVELBINE; NIMOTUZUMAB; PANITUMUMAB; PLACEBO;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; GLIOMA; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; NASOPHARYNX CANCER; NONHUMAN; PANCREAS CANCER; PROGNOSIS; RECEPTOR AFFINITY; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

EID: 79959759891     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3022014     Document Type: Review

References (72)

1. Mendelsohn, J.; Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 2006, 33, 369-385.
2. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358, 1160-1174.
3. Weinstein, I.B.; Joe, A. Oncogene addiction. Cancer Res. 2008, 68, 3077-3080; discussion 3080.
4. Lièvre, A.; Bachet, J.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J.; Côté, J.; Tomasic, G.; Penna, C.; Ducreux, M., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66, 3992-3995.
5. Di Fiore, F.; Blanchard, F.; Charbonnier, F.; Le Pessot, F.; Lamy, A.; Galais, M. P.; Bastit, L.; Killian, A.; Sesboüé, R.; Tuech, J.J., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 2007, 96, 1166-1169.
6. De Roock, W.; Piessevaux, H.; De Schutter, J.; Janssens, M.; De Hertogh, G.; Personeni, N.; Biesmans, B.; Van Laethem, J.; Peeters, M.; Humblet, Y., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 2008, 19, 508-515.
7. Lièvre, A.; Bachet, J.; Boige, V.; Cayre, A.; Le Corre, D.; Buc, E.; Ychou, M.; Bouché, O.; Landi, B.; Louvet, C., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26, 374-379.
8. Amado, R.G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D. J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 1626-1634.
9. Schneider, C.; Heigener, D.; Schott-von-Römer, K.; Gütz, S.; Laack, E.; Digel, W.; Guschall, W.; Franke, A.; Bodenstein, H.; Schmidtgen, C., et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J. Thorac. Oncol. 2008, 3, 1446-1453.
10. Linardou, H.; Dahabreh, I.J.; Kanaloupiti, D.; Siannis, F.; Bafaloukos, D.; Kosmidis, P.; Papadimitriou, C.A.; Murray, S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9, 962-972.
11. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567-578.
12. Vermorken, J.B.; Trigo, J.; Hitt, R.; Koralewski, P.; Diaz-Rubio, E.; Rolland, F.; Knecht, R.; Amellal, N.; Schueler, A., Baselga, J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 2007, 25, 2171-2177.
13. Jonker, D.J.; O'Callaghan, C.J.; Karapetis, C.S.; Zalcberg, J.R.; Tu, D.; Au, H.; Berry, S.R.; Krahn, M.; Price, T.; Simes, R.J., et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007, 357, 2040-2048.
14. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345.
15. Giusti, R.M.; Shastri, K.; Pilaro, A.M.; Fuchs, C.; Cordoba-Rodriguez, R.; Koti, K.; Rothmann, M.; Men, A.Y.; Zhao, H.; Hughes, M., et al. U.S. Food and Drug Administration approval: Panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin. Cancer Res. 2008, 14, 1296-1302.
16. Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353, 123-132.
17. Cappuzzo, F.; Ciuleanu, T.; Stelmakh, L.; Cicenas, S.; Szczésna, A.; Juhász, E.; Esteban, E.; Molinier, O.; Brugger, W.; Melezínek, I., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010, 11, 521-529.
18. Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1960-1966.
19. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003, 21, 2237-2246.
20. Kim, E.S.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Wu, Y.; Li, L.; Watkins, C.L.; Sellers, M.V.; Lowe, E.S., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008, 372, 1809-1818.
21. Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Implications for clinical practice and open issues. Lung Cancer 2011, 72, 3-8.
22. Di Cosimo, S.; Baselga, J. Pharmacodynamic endpoints in primary breast cancer. Ann. Oncol. 2007, 18 (Suppl.9), ix21-ix23.
23. Hales, R.K.; Banchereau, J.; Ribas, A.; Tarhini, A.A.; Weber, J.S.; Fox, B.A.; Drake, C.G. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann. Oncol. 2010, 21, 1944-1951.
24. Reardon, D.A.; Galanis, E.; Degroot, J.F.; Cloughesy, T.F.; Wefel, J.S.; Lamborn, K.R.; Lassman, A.B.; Gilbert, M.R.; Sampson, J.H.; Wick, W., et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology 2011, 13, 353-361.
25. Peréz-Soler, R.; Saltz, L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J. Clin. Oncol. 2005, 23, 5235-5246.
26. Lacouture, M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 2006, 6, 803-812.
27. Wolchok, J.D.; Hoos, A.; O'Day, S.; Weber, J.S.; Hamid, O.; Lebbé, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 2009, 15, 7412-7420.
28. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
29. Pérez, R.; Pascual, M.; Macías, A.; Lage, A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res. Treat. 1984, 4, 189-193.
30. Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 2008, 13, 472-482.
31. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436-444.
32. Boland, W.K.; Bebb, G. Nimotuzumab: A novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin. Biol. Ther. 2009, 9, 1199-1206.
33. Rodríguez, M.O.; Rivero, T.C.; del Castillo Bahi, R.; Muchuli, C.R.; Bilbao, M.A.; Vinageras, E.N.; Alert, J.; Galainena, J.J.; Rodríguez, E.; Gracias, E., et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol. Ther. 2010, 9, 343-349.
34. Rojo, F.; Gracias, E.; Villena, N.; Cruz, T.; Corominas, J.M.; Corradino, I.; Cedeño, M.; Campas, C.; Osorio, M.; Iznaga, N., et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin. Cancer Res. 2010, 16, 2474-2482.
35. Basavaraj, C.; Sierra, P.; Shivu, J.; Melarkode, R.; Montero, E.; Nair, P. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol. Ther. 2010, 10, 673-681.
36. Strumberg, D.; Schultheis, B.; Scheulen, M.E.; Hilger, R.A.; Krauss, J.; Marschner, N.; Lordick, F.; Bach, F.; Reuter, D.; Edler, L., et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2010, unpublished.
37. Boland, W.; Bebb, G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics 2010, 4, 289-298.
38. Massimino, M.; Bode, U.; Biassoni, V.; Fleischhack, G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin. Biol. Ther. 2011, 11, 247-256.
39. Lam, C.; Bouffet, E.; Bartels, U. Nimotuzumab in pediatric glioma. Future Oncol. 2009, 5, 1349-1361.
40. Ramos, T.C.; Figueredo, J.; Catala, M.; González, S.; Selva, J.C.; Cruz, T.M.; Toledo, C.; Silva, S.; Pestano, Y.; Ramos, M., et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biol. Ther. 2006, 5, 375-379.
41. Allan, D.G.P. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005, 10, 760-761.
42. YM BioSciences: Products: Nimotuzumab: Safety Profile. http://www.ymbiosciences.com/products/nimotuzumab/safety_profile.php/ (accessed 18 March 2011).
43. Crombet, T.; Osorio, M.; Cruz, T.; Roca, C.; del Castillo, R.; Mon, R.; Iznaga-Escobar, N.; Figueredo, R.; Koropatnick, J.; Renginfo, E., et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol. 2004, 22, 1646-1654.
44. Ramakrishnan, M.S.; Eswaraiah, A.; Crombet, T.; Piedra, P.; Saurez, G.; Iyer, H.; Arvind, A.S. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs 2009, 1, 41-48.
45. Huang, X.; Yi, J.; Gao, L.; Xu, G.; Jin, J.; Yang, W.; Lu, T.; Wu, S.; Wu, R.; Hu, W., et al. Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 2007, 29, 197-201.
46. Gupta, M.; Madholia, V.; Gupta, N.; Bhowmik, K. Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck. J. Clin. Oncol. 2010, 28, 15s, Abstract 5565.
47. Kim, Y.; Sasaki, Y.; Lee, K.; Rha, S.; Park, S.; Boku, N.; Komatsu, Y.; Kim, T.; KIm, S.; Sakata, Y. Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results. J. Clin. Oncol. 2011, 29, 4s, Abstract 87.
48. Bebb, G.; Smith, C.; Rorke, S.; Boland, W.; Nicacio, L.; Sukhoo, R.; Brade, A. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother. Pharmacol. 2010, 67, 837-45.
49. Choi, H.J.; Sohn, J.H.; Lee, C.G.; Shim, H.S.; Lee, I.; Yang, W.I.; Kwon, J.E.; Kim, S.K.; Park, M.; Lee, J.H., et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 2011, 71, 55-59.
50. Crombet, T.; Cabanas, R.; Alert, J.; Valdés, J.; González, M.C.; Pedrayes, J.L.; Ríos, M.; Leyva, T.; Herrera, R.; Avila, M. Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: preliminary results from a phase II study. Eur. J. Cancer Suppl. 2009, 7, 497.
51. ClinicalTrials.gov: A service from the U.S. National Institutes of Health. http://clinicaltrials.gov/ (accessed 18 March 2011).
52. Weiner, L.M.; Carter, P. Tunable antibodies. Nat. Biotechnol. 2005, 23, 556-557.
53. Li, S.; Schmitz, K.R.; Jeffrey, P.D.; Wiltzius, J.J.W.; Kussie, P.; Ferguson, K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7, 301-311.
54. Yang, X.D.; Jia, X.C.; Corvalan, J.R.; Wang, P.; Davis, C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 2001, 38, 17-23.
55. Talavera, A.; Friemann, R.; Gómez-Puerta, S.; Martinez-Fleites, C.; Garrido, G.; Rabasa, A.; López-Requena, A.; Pupo, A.; Johansen, R.F.; Sánchez, O., et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009, 69, 5851-5859.
56. Akashi, Y.; Okamoto, I.; Iwasa, T.; Yoshida, T.; Suzuki, M.; Hatashita, E.; Yamada, Y.; Satoh, T.; Fukuoka, M.; Ono, K., et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br. J. Cancer 2008, 98, 749-755.
57. Garrido, G.; Tikhomirov, I.A.; Rabasa, A.; Yang, E.; Gracia, E.; Iznaga, N.; Fernández, L.E.; Crombet, T.; Kerbel, R.; Pérez, R. Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile. Cancer Biol. Ther. 2011, 11, 1-10.
58. Khambata-Ford, S.; Harbison, C.T.; Hart, L.L.; Awad, M.; Xu, L.; Horak, C.E.; Dakhil, S.; Hermann, R.C.; Lynch, T.J.; Weber, M.R. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 918-927.
59. Schmitz, K.R.; Ferguson, K.M. Interaction of antibodies with ErbB receptor extracellular regions. Exp. Cell Res. 2009, 315, 659-670.
60. Crombet-Ramos, T.; Rak, J.; Pérez, R.; Viloria-Petit, A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int. J. Cancer 2002, 101, 567-575.
61. Lammerts van Bueren, J.J.; Bleeker, W.K.; Brännström, A.; von Euler, A.; Jansson, M.; Peipp, M.; Schneider-Merck, T.; Valerius, T.; van de Winkel, J.G.J.; Parren, P.W.H.I. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc. Natl. Acad. Sci. USA 2008, 105, 6109-6114.
62. Diaz Miqueli, A.; Rolff, J.; Lemm, M.; Fichtner, I.; Perez, R.; Montero, E. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br. J. Cancer 2009, 100, 950-958.
63. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11, 69-82.
64. Viloria-Petit, A.; Crombet, T.; Jothy, S.; Hicklin, D.; Bohlen, P.; Schlaeppi, J.M.; Rak, J.; Kerbel, R.S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res. 2001, 61, 5090-5101.
65. Garrido, G.; Lorenzano, P.; Sánchez, B.; Beausoleil, I.; Alonso, D.F.; Pérez, R.; Fernández, L.E. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol. Immunother. 2007, 56, 1701-1710.
66. Garrido, G.; Rabasa, A.; Sánchez, B.; López, M.V.; Blanco, R.; López, A.; Hernández, D.R.; Pérez, R.; Fernández, L.E. J. Immunol. Submitted for publication, 2011.
67. Heimberger, A.B.; Sampson, J.H. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin. Biol. Ther. 2009, 9, 1087-1098.
68. Ramírez, B.S.; Alpízar, Y.A.; Fernández, D.R.H.; Hidalgo, G.G.; Capote, A.R.; Rodríguez, R.P.; Fernández, L.E. Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine. Vaccine 2008, 26, 4918-4926.
69. Weiner, L.M.; Dhodapkar, M.V.; Ferrone, S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009, 373, 1033-1040.
70. Hilchey, S.P.; Hyrien, O.; Mosmann, T.R.; Livingstone, A.M.; Friedberg, J.W.; Young, F.; Fisher, R.I.; Kelleher, R.J.; Bankert, R.B.; Bernstein, S.H. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 2009, 113, 3809-3812.
71. Herrmann, F.; Lehr, H.; Drexler, I.; Sutter, G.; Hengstler, J.; Wollscheid, U.; Seliger, B. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res. 2004, 64, 215-220.
72. Hoos, A.; Parmiani, G.; Hege, K.; Sznol, M.; Loibner, H.; Eggermont, A.; Urba, W.; Blumenstein, B.; Sacks, N.; Keilholz, U., et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 2007, 30, 1-15.